{"id":"ivf-m-hp-inj","safety":{"commonSideEffects":[{"rate":null,"effect":"Ovarian hyperstimulation syndrome (OHSS)"},{"rate":null,"effect":"Injection site reactions (pain, bruising, erythema)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Abdominal pain or bloating"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1631333","moleculeType":"Oligonucleotide","molecularWeight":"8971.40"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This injectable gonadotropin binds to FSH receptors on ovarian granulosa cells, promoting follicular growth and maturation during controlled ovarian hyperstimulation. By elevating circulating FSH levels, it enables the development of multiple mature oocytes suitable for retrieval during in vitro fertilization procedures. The 'HP' designation typically indicates a highly purified formulation with reduced impurities compared to earlier urinary-derived preparations.","oneSentence":"IVF-M HP is a recombinant human follicle-stimulating hormone (FSH) that stimulates ovarian follicle development and estrogen production in women undergoing assisted reproductive therapy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:50:35.133Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anovulation or oligoovulation in women with polycystic ovary syndrome (PCOS) undergoing assisted reproduction"},{"name":"Controlled ovarian hyperstimulation for in vitro fertilization (IVF)"},{"name":"Ovulation induction in infertile women"}]},"trialDetails":[{"nctId":"NCT02458768","phase":"PHASE4","title":"Multicenter, Randomized, Open Label, Parallel Study to Evaluate the Efficacy & Safety of IVF-M HP Inj. vs. Menopur® Inj.","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2013-07","conditions":"Infertility, Female","enrollment":112}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"IVF-M HP Inj.","genericName":"IVF-M HP Inj.","companyName":"LG Life Sciences","companyId":"lg-life-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IVF-M HP is a recombinant human follicle-stimulating hormone (FSH) that stimulates ovarian follicle development and estrogen production in women undergoing assisted reproductive therapy. Used for Anovulation or oligoovulation in women with polycystic ovary syndrome (PCOS) undergoing assisted reproduction, Controlled ovarian hyperstimulation for in vitro fertilization (IVF), Ovulation induction in infertile women.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}